Treosulfan-based conditioning regimen in allo-HSCT in adult patients with inborn errors of immunity and rare disorders. 2. “Up-front” allogeneic stem cell transplantation in elderly patients with ...

本次“再生障碍性贫血”专场特邀中国医学科学院血液病医院的张凤奎教授担任大会主席，施普林格·自然集团的大中华区总裁Arnout Jacobs先生作为特邀嘉宾致开场词，北京协和医院的韩冰教授担任主要讲者，来自法国的Régis Peffault de Latour教授、日本的Shinji Nakao教授和韩国的Jun Ho Jang教授作为讨论嘉宾参与了热点问题的探讨。

Keywords: Allogeneic hematopoietic stem cell transplantation, allo-HCT, inborn errors of immunity, allo-HSCT Important Note: All contributions to this Research Topic must be within the scope of the ...

HSCT： 1）来自中国的单中心回顾性临床研究，儿童AA患者接受UCBT、haplo-HSCT及MSD-HSCT，结果显示，虽然儿童SAA患者首选MSD-HSCT，但是在缺乏同胞全相合 ...

3 Allogeneic HSCT has been reported to be feasible and effective in the short term and medium term (ie, 6 months to 3 years), with donors being HLA-identical siblings (most cases), a haplo-identical ...

The restricted mean leukemia-free survival up to 5 years was longer among patients who received an allogeneic transplant than among patients who received another type of consolidation therapy.

▎药明康德内容团队编辑白血病是一类起源于造血干细胞的恶性克隆性疾病，由于是血液系统的恶性肿瘤，又被人们称为“血癌”。据国际癌症研究机构数据显示，2022年全球新发白血病为48.7万例，导致死亡人数为30.5万，是第10大致死癌症；中国新发白血病人数为 ...

随着科技的发达，单倍型相合移植（Haploidentical Stem Cell Transplantation， Haplo-HSCT）已为许多无亲兄弟姐妹的患者带来很多益处。就算捐赠者并不属于“搭配型”干细胞捐赠者（比如亲生父母属50%相匹配），患者也较少会出现排斥现象。” 白血病没有明确因素 ...

Three randomised controlled trials of haematopoietic stem cell transplantation (HSCT) in systemic sclerosis (SSc) demonstrated long-term survival benefits, induction of clinically meaningful, ...

MRD status before allo-HSCT is a strong prognostic factor for OS, DFS, and CIR in AML and MDS patients. MRD-negative patients showed significantly better OS and DFS compared to MRD-positive ...